A Phase 1/2 Study of Inhaled KB707 in Patients with Advanced Solid Tumor Malignancies Affecting the Lungs

2025-522723-98-00 · tracked via the Priya Life Science EU tracker

Sponsor

Krystal Biotech Inc.

Sponsor type

Pharmaceutical company

Therapeutic area

Neoplasms

Decision date

30/06/2026

Enrollment target

Sites

France, Spain

Condition studied

solid tumor

Investigational medicinal product(s)

KB707DOCETAXEL

Eligibility

Age group

18-64 years, 65+ years

Sex

Female, Male

Primary endpoint

Frequency, severity, and relatedness of Adverse Events (AEs) and Serious Adverse Events (SAEs)

Endpoint detail

Incidence of Dose-Limiting Toxicity (DLT) by dose cohorts, Assessment of the objective response rate (ORR), complete response (CR), clinical benefit rate (CBR), duration of response (DOR), time to response (TTR), progression free survival (PFS), and overall survival (OS)

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-522723-98-00 on CTIS ↗ ← All trials in the EU